Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

Thu, October 15, 2026 at 1:33 PM UTC 3 min read

RARE announced the approval of its drug Fayuvi, leading to the sale of a Priority Review Voucher (PRV) for $203 million, marking the second PRV sale within a week. This significant transaction highlights the company's ability to monetize its regulatory assets, potentially enhancing its financial position and investor confidence. The approval and subsequent sale underscore RARE's strategic advancements in the biotech sector, which could lead to further growth opportunities.

Read full article →

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results

Tue, September 22, 2026 at 7:09 PM UTC 2 min read

RARE stock experienced a notable increase this week as investors shifted their focus from recent trial failures to the upcoming launches of gene therapies. This optimism suggests that the market is prioritizing the potential long-term benefits of RARE's innovative treatments over short-term setbacks. For investors, this indicates confidence in the company's future growth prospects and the viability of its product pipeline.

Read full article →